Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azacitidine + thalidomide
- Development stage
- Unknown
- Lead developer
- Tel Aviv Sourasky Medical Center
- Modality
- Small Molecules
- Administration
- Subcutaneous, Oral, Intravenous
01
Overview
This combination therapy consists of azacitidine (5-aza-cytidine) and thalidomide, currently being investigated by the Tel-Aviv Sourasky Medical Center for the treatment of higher-risk myelodysplastic syndromes (MDS). Azacitidine is a pyrimidine nucleoside analog that functions as a DNA methyltransferase inhibitor, promoting DNA hypomethylation and the restoration of normal hematopoiesis by reactivating silenced tumor suppressor genes. Thalidomide is an immunomodulatory drug (IMiD) that exerts anti-angiogenic, anti-inflammatory, and pro-apoptotic effects, partially through its interaction with the cereblon E3 ubiquitin ligase complex. The dual-action approach of this regimen is intended to enhance therapeutic efficacy in patients with intermediate-2 or high-risk MDS who often have poor prognoses with monotherapy.
- Brand names
- VidazaThalomid
- Other names
- 5-aza-cytidine + thalidomideAzacitidine and Thalidomide
02
Targets
DNMT1 (DNA (cytosine-5)-methyltransferase 1)CRBN (Cereblon)
Beyond the preview
Go deeper on azacitidine + thalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azacitidine + thalidomide.